Aurora Kinases-IN-3_product_DataBase

Bioactivity	Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10[1].
Target	AURKB
Invitro	Aurora Kinases-IN-3 (Compound 15a) (40 nM; 6 h) disrupts localization of AURKB, MKLP1, and PLK at the spindle midzone to prevent spindle midzone microtubule assembly in RPE-MYCBCL2 cells. Aurora Kinases-IN-3 disrupts the localization of AURKB as early as anaphase, producing downstream consequences that blocked cytokinesis[1].Aurora Kinases-IN-3 (1-10 μM; 3 days) shows wide spectrum of growth suppression in human cancer cell lines[1]. Cell Viability Assay[1] Cell Line:
In Vivo	Aurora Kinases-IN-3 (Compound 15a) (50 mg/kg; oral; twice a day for 7 days) 抑制小鼠肺部肿瘤的生长[1]。 Animal Model:
Name	Aurora Kinases-IN-3
CAS	2840558-83-8
Formula	C20H16F3N3O4
Molar Mass	419.35
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Lv G, et al. 2-Phenoxy-3, 4'-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114904.

PeptideDB